Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-16T15:06:29.019Z Has data issue: false hasContentIssue false

Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression

Published online by Cambridge University Press:  02 January 2018

Jane A. Hicks*
Affiliation:
Psychopharmacology Unit, University of Bristol
Spilios V. Argyropoulos
Affiliation:
Psychopharmacology Unit, University of Bristol
Ann S. Rich
Affiliation:
University of Bristol
Jon Nash
Affiliation:
Psychopharmacology Unit, University of Bristol
Caroline J. Bell
Affiliation:
Psychopharmacology Unit, University of Bristol
Chris Edwards
Affiliation:
Bristol-Myers Squibb, 141 Staines Road, Hounslow, Middlesex TW3 3JA
David J. Nutt
Affiliation:
Psychopharmacology Unit, University of Bristol
Susan J. Wilson
Affiliation:
Psychopharmacology Unit, University of Bristol
*
David Nutt, Psychopharmacdogy Unit, University Walk, Bristol BS8 ITD, UK
Rights & Permissions [Opens in a new window]

Abstract

Background

Sleep effects of antidepressants are important clinically and for elucidating mechanism of action: selective serotonin reuptake inhibitors disturb sleep and 5-HT2 receptor-blocking compounds may enhance sleep quality.

Aims

To compare the objective and subjective effects on sleep of paroxetine and nefazodone in patients with moderate to severe depression.

Method

Forty patients with depression were randomised to take paroxetine 20-40 mg/day or nefazodone 400–600 mg/day for 8 weeks. Objective and subjective quality of sleep and depression measures were assessed throughout.

Results

Nefazodone significantly increased objective sleep efficiency and total sleep time, and improved subjective sleep on days 3 and 10. Paroxetine decreased sleep efficiency early in treatment and some sleep disruption remained at week 8. Paroxetine but not nefazodone produced marked suppression of rapid eye movement (REM) sleep.

Conclusions

Nefazodone improves sleep in early treatment compared with paroxetine in patients with moderate to severe depression. These effects are seen within the first 2 weeks of treatment and diminish thereafter.

Information

Type
Papers
Copyright
Copyright © 2002 The Royal College of Psychiatrists 
Figure 0

Table 1Baseline demographic and clinical data

Figure 1

Table 2Primary reasons for discontinuation

Figure 2

Table 3Objective (EEG) sleep

Figure 3

Fig. 1Mean sleep efficiency. Error bars indicate s.e.m.

Figure 4

Fig. 2Mean number of awakenings. Error bars indicate s.e.m.

Figure 5

Fig. 3Mean REM latency. Error bars indicate s.e.m.

Figure 6

Fig. 4Subjective sleep measures — change from baseline St Mary's Hospital Sleep Questionnaire Quality of sleep. Error bars indicate s.e.m. *P<0.05.

Figure 7

Table 4Subjective sleep parameters (St Mary's Hospital Sleep Questionnaire). All data presented as mean (s.d.)

Figure 8

Fig. 5Hamilton Rating Scale for Depression (HRSD) scores last observation carried forward, intention to treat. Error bars indicate s.e.m.

Figure 9

Table 5Number of non-serious adverse events occurring in more than 5% of patients (% of patients reporting)

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.